The Promise of RNAi Therapeutics for Cardiovascular Disease Treatment
Kevin Fitzgerald from Alnylam Pharmaceuticals explains the potential of RNA interference for treating disease and highlights recent clinical trial successes.
The Promise of RNAi Therapeutics for Cardiovascular Disease Treatment
The Promise of RNAi Therapeutics for Cardiovascular Disease Treatment
Kevin Fitzgerald from Alnylam Pharmaceuticals explains the potential of RNA interference for treating disease and highlights recent clinical trial successes.
Kevin Fitzgerald from Alnylam Pharmaceuticals explains the potential of RNA interference for treating disease and highlights recent clinical trial successes.
The genetically modified bacteria spark an RNAi response in the parasite that leads to self-destruction—and perhaps a path to combatting colony collapse disorder.
A new study adds to the evidence that mammalian cells can use small interfering RNAs to defend against viruses, but questions remain about physiological importance.
A recent CRISPR study contradicted years of RNA interference research on a well-studied cancer drug target. But is it the last nail in the coffin for RNAi as a screening tool?
Plants and fungi can use conserved RNA interference machinery to regulate each other’s gene expression—and scientists think they can make use of this phenomenon to create a new generation of pesticides.
Successful late-stage clinical trials could mark the maturation of a new drug development platform, but the path to commercialization is not without hurdles.